A meta-analysis of mortality in rheumatic diseases

Toledano, Esther; Candelas, Gloria; Rosales, Zulema; Prada, C. Martínez; León, Leticia; Abásolo, Lydia; Loza, Estíbaliz; Carmona, Loreto; Tobías, Aurelio; Jover, Juan A.

doi:10.1016/j.reumae.2012.05.002

Cited by 20 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the Korean Standard Classification of Diseases, Seventh Revision (KCD‐7), the diagnosis code of RD includes RA, osteoporosis, and OA (Appendix S1). Osteoporosis and OA are considered RDs in previous studies (Camafeita, Lamas, Calvo, Lopez, & Fernandez‐Gutierrez, ; Monjardino, Lucas, & Barros, ; Reis & Viana Queiroz, ; Toledano et al, ). Similar to other RDs, they are commonly characterized by metabolic pathologies such as alteration of osteoblast or vitamin D (Corrado, Maruotti, & Cantatore, ; Rossini et al, ).…”

Section: Methodsmentioning

confidence: 99%

Liver enzyme abnormalities of inpatients with rheumatic diseases: A 10‐year retrospective study in a Korean medicine hospital

Lee

Kang

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

Herbal medicines have been used as a treatment option for rheumatic disease (RD), but they often produce liver enzyme abnormality. This study examines the incidence of herb-induced liver injury (HILI) and the relationship between risk factors and liver enzyme abnormality (LEA) in inpatients with RD. HILI was analyzed using the Roussel Uclaf causality assessment method liver injury criteria and causality assessment. Multivariable analysis was performed to assess the relationship between patient characteristics and LEA in RD. The features of LEA were also examined in each RD. Among 352 patients included in this study, 105 patients showed LEA on admission, of which 6 had fulfilled the Roussel Uclaf causality assessment method criteria. The incidence risks of LEA and HILI were 12.55% and 0.58%, respectively. Multivariable analysis showed that LEA on admission and occasional use of alcohol could be risk factors for LEA on follow-up. In an additional analysis with each RD, all rheumatoid arthritis patients with LEA were taking nonsteroidal anti-inflammatory drugs, steroids, and disease-modifying antirheumatic drugs, and 4 out of 5 gout patients with LEA were taking steroids. The use of herbal medicine in RD is relatively safe. However, regular monitoring of liver enzyme tests and examination of alcohol consumption are required.

show abstract

Section: Methodsmentioning

confidence: 99%

Liver enzyme abnormalities of inpatients with rheumatic diseases: A 10‐year retrospective study in a Korean medicine hospital

Lee

Kang

et al. 2018

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…At every cycle of the model, the patient could die of natural causes. Since patients with RA showed a higher mortality risk than the general population, as reported in a recent meta‐analysis where a standardized mortality rate of 1.44 (95% confidence interval [95% CI] 1.23–1.69) was calculated , in our study a mortality risk of 1.5 times the average Italian population mortality risk was applied for RA patients comprised in the age intervals 35–50, 51–65, and >65 years, based on Italian demographic data .…”

Section: Methodsmentioning

confidence: 99%

Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis

Quartuccio

Bidino²,

Ruggeri

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Rituximab (RTX) is licensed for second-line treatment of rheumatoid arthritis (RA) after first tumor necrosis factor (TNF) inhibitor failure. RTX is generally administered intravenously at 1 gm 2 weeks apart, and the retreatment is scheduled at the time of clinical relapse (regimen 1). A more intensive regimen is proposed with a fixed full cycle after 6 months (regimen 2) if remission is not reached. A cost-effectiveness analysis (CEA) compared these 2 regimens of RTX administration in patients with longstanding RA based on data provided by an observational study.Methods. An observational retrospective study was conducted on 102 patients, enrolled in 3 hospitals and followed for ‡12 months. Forty-seven patients followed regimen 1, while 55 patients followed regimen 2. A CEA based on a Markov model was conducted. A lifelong and social perspective was adopted. CEA was conducted for the entire cohort and for the 2 subgroups separately (patients with positive rheumatoid factor and/or anti-cyclic citrullinated peptide and failures to TNF inhibitors). Results. Results for the overall sample show at 10, 20, and 30 years that regimen 1 is less costly and associated with a higher quality of life compared to regimen 2. Probabilistic sensitivity analysis at 10 years estimated a probability of 95.1% for regimen 1 to be cost effective given a willingness to pay of e35,000/quality-adjusted life year, while for seropositive patients and for TNF failures it was estimated to be 92% and 92.7%, respectively. Conclusion. In longstanding RA, cost effectiveness of RTX retreatment at clinical relapse was found to be at least equivalent to the more intensive regimen proposed.

show abstract

“…These rheumatic diseases are chronic multisystemic illnesses that may be associated with significant mortality and morbidity [3]. In addition to disease-related complications, adverse events related to treatment may aggravate the risk of mortality [4].…”

Section: Introductionmentioning

confidence: 99%

Overall and Sex-specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Meta-analysis

Lee

Song

2018

J Rheum Dis

View full text Add to dashboard Cite

Objective. This study examined the all-cause and sex-specific standardized mortality ratios (SMRs) in patients with spondyloarthropathy. Methods. Studies examining the all-cause and/or cause-specific SMRs in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) compared to the general population were surveyed using MEDLINE, EMBASE, and Cochrane databases and manual searches. A meta-analysis of the all-cause and sex-specific SMRs in patients with rheumatic diseases was then performed. Results. In total, 7 comparisons (5 PsA and 2 AS) from 6 reports met the inclusion criteria. Disease-specific meta-analysis showed that the pooled SMR was 1.299 (95% confidence interval [CI] 1.092∼1.605, p=0.015) for PsA and 1.784 (95% CI 1.576∼2.020, p＜0.001) for AS. Meta-analysis showed that the SMRs of PsA and AS were significantly higher (1.299 to 1.784 times) than those in the general population. The age-and sex-adjusted SMR was highest for AS (1.784), followed by PsA (1.299). Moreover, sex-specific meta-analysis showed that the all-cause SMRs were increased in female and male patients with PsA. On the other hand, mortality increased in male patients with AS (SMR 1.834), whereas there was no significant increase in female patients with AS. Conclusion. All-cause mortality is higher in patients with PsA and AS compared to the general population. On the other hand, the mortality was higher in males with AS but not in females. (J Rheum Dis 2018;25:197-202)

show abstract

A meta-analysis of mortality in rheumatic diseases

Cited by 20 publications

References 39 publications

Liver enzyme abnormalities of inpatients with rheumatic diseases: A 10‐year retrospective study in a Korean medicine hospital

Liver enzyme abnormalities of inpatients with rheumatic diseases: A 10‐year retrospective study in a Korean medicine hospital

Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis

Overall and Sex-specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Meta-analysis

Contact Info

Product

Resources

About